SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Ceregene, Inc. today
announced that Jeffrey M. Ostrove, Ph.D., president and chief executive
officer, will present at the JPMorgan 26th Annual Healthcare Conference in
San Francisco, CA on Thursday, January 10th at 11:30 a.m. PST.
"We look forward to participating in this pre-eminent healthcare
conference and providing a Ceregene update to the investment community,"
stated Dr. Ostrove. "2007 was a positive year for us during which time we
raised our Series C financing, signed a corporate partnership deal with
Genzyme and announced encouraging data from both our clinical-stage
Parkinson's disease and Alzheimer's disease programs. We expect to report
Phase 2 data from our controlled CERE-120 Parkinson's disease study late
this year, which could lead to a Phase 3 clinical study in 2009. We also
look forward to the initiation of a larger, controlled Phase 2 trial of
CERE-110 in Alzheimer's disease later this year."
Ceregene, Inc. is a San Diego-based biotechnology company focused on
the delivery of nervous system growth factors for the treatment of
neurodegenerative disorders using gene delivery. Ceregene's clinical
programs include CERE-110, an AAV2 based vector expressing nerve growth
factor that is currently in Phase 1/2 studies for the treatment of
Alzheimer's disease, and CERE-120 (AAV2-Neurturin) which recently completed
enrollment of a controlled Phase 2 study for Parkinson's disease. CERE-130
and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease)
and ocular disorders, respectively. Ceregene was launched in January 2001
and is a former subsidiary of Cell Genesys, Inc. (Nasdaq: CEGE). The
company's investors include Alta Partners, MPM Capital, Investor Growth
Capital and Cell Genesys as well as Hamilton BioVentures and California
SOURCE Ceregene, Inc.